Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
Solid Biosciences signed a gene therapy agreement with CDMO Andelyn Biosciences for the use of Solid’s proprietary, next-generation capsid, AAV-SLB101. Solid grants Andelyn a non-exclusive worldwide ...
PHILADELPHIA--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company pioneering advances in tissue-targeted AAV gene therapy, today announces the publication of a seminal research ...
A new study in Human Gene Therapy describes a machine learning (ML) model that can be used as a surrogate for laborious in vitro experiments. This in silico approach aims to increase the fitness of ...
Ready-to-use solution for Amperia benchtop platform supports rapid, reliable quantification across a range of serotypes Kits incorporate Thermo Fisher Scientific’s CaptureSelect affinity reagents for ...
Learn how viral vector release testing for AAV and lentiviral vectors utilizes orthogonal assays for titer, capsid content, ...
Adeno-associated virus (AAV) capsids are an effective mechanism for delivering gene therapies intended for therapeutic use. A critical production step is the separation of full capsids from empty ones ...
This article is based on a poster originally authored by Jennifer Yin, Kimiko Kearney, Abigail Keller, Rodriel Bautista, Chelsea Pratt, Dipika Gurnani and Nathan Sepulveda. Gene therapy is an advanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results